Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors Save
Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied to baricitinib and upadacitinib.
Author Disclosures
- Jack Cush, MD: Advisor/Consultant: Abbvie, Novartis, Amgen, BMS. (Investigator on Pfizer 1133 trial)
- Roy Fleischmann, MD: Consultant: AbbVie, Amgen, BMS, Galvani, Gilead, GSK, Jansen, Eli Lilly, Novartis, Pfizer, Sanofi Aventis, UCB Clinical Trial Grants: AbbVie, Amgen, BMS, Flexion, Galapagos, Genentech, Gilead, GSK, Horizon, Eli Lilly, Novartis, Noven, Pfizer, Regeneron, Roche, Samumed, Sanofi Aventis, Selecta, Teva, UCB, Viela, VORSO
- Artie Kavanaugh, MD: Consultancy – AbbVie, Amgen, Celgene, Chugai, Corrona, Covagen, Galapagos, Genentech/Roche, Janssen, Merck, Novartis, Pfizer, Sanofi, UCB; Research funding – AbbVie, Amgen, Astellas, Biogen-Idec, BMS, Celgene, Genentech/Roche, HGS, Janssen, Kirin, Pfizer, Regeneron, Sanofi, UCB
- Allan Gibofsky, MD: Speaker-AbbVie, Lilly, Pfizer Consultant-AbbVie, Pfizer Shareholder-Abbvie, Pfizer; Special Employee – FDA
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.